Product Details
Synonyms
GTPase Kras, K-Ras 2, Ki-Ras, c-K-ras, c-Ki-ras, KRAS2, RASK2, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, KI-RAS, KRAS1, KRAS2, NS, NS3, RASK2, KRAS
Source
Human KRAS (G12S) Protein, His Tag (KRS-H5144) is expressed from E. coli cells. It contains AA Thr 2 - Cys 185 (Accession # P01116-2 (G12S)).
Request for sequenceMolecular Characterization

Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 23.0 kDa. The protein migrates as 27-28 kDa under reducing (R) condition (SDS-PAGE).
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
>95% as determined by SEC-HPLC.
Formulation
Lyophilized from 0.22 μm filtered solution in 20 mM Tris, 500 mM NaCl, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE

Human KRAS (G12S) Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
SEC-HPLC

The purity of Human KRAS (G12S) Protein, His Tag (Cat. No. KRS-H5144) was greater than 95% as determined by SEC-HPLC.
Bioactivity
The specific activity of KRAS was determined to b > 350 pmol/min/mg in a GTPase-Glo assay using GTP solution substrate (QC tested).
Protocol
Customer Reviews Writing Reviews

Background
Recent Advances
- English Name:
GTPase KRas
- Category:
- Approved Drugs:
0 Details
- Drugs in Clinical Trials:
40 Details
- Highest Development Stage:
Phase 2 Clinical



















